Toxicity differences in CDK 4/6 inhibitors seen in Asian and Pacific Islanders. Real-world treatment patterns and clinical outcomes among patients with HR+/HER2- advanced/metastatic breast cancer ...
Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results